SWOG / S1931
Trial Overview
Official Title
Comparing The Outcome Of Immunotherapy-Based Drug Combination Therapy With Or Without Surgery To Remove The Kidney In Metastatic Kidney Cancer
Study Purpose
To compare Standard Systemic Therapy alone to Standard Systemic Therapy plus surgery to remove all or part of the kidney with tumor.
Diagnosis
Patients who have kidney cancer that has spread outside of their kidney.Eligibility
Participants must have a histologically proven diagnosis of clear cell or non-clear cell renal cell carcinoma.
Participants with collecting duct carcinoma histology are not eligible.
Participants with multifocal or bilateral tumors are eligible
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Intervention
This study has 2 study groups:
- Group 1: Patients in this group will continue to receive standard systemic therapy until their disease gets worse or the side effects are too great.
- Group 2: Patients in this group will continue to receive standard systemic therapy, but patients will also have surgery to remove part or all of your kidney.
For more information, click the link below:
https://clinicaltrials.gov/study/NCT04510597?term=S1931&rank=1